Requires coverage of clinician-administered drugs without additional financial penalties or certain limitations on location of administration of drugs.

2026-2027 Regular Session Introduced by Carol Murphy

Health plans must cover clinician-administered drugs with no extra costs or location-based limits, ensuring coverage parity across settings.

Introduced, Referred to Assembly Financial Institutions and Insurance Committee

Summary of Bill A 5270 (New Jersey, 222nd Legislature)

Purpose and intent

The bill requires coverage for clinician-administered drugs by certain health plans without imposing additional financial penalties or specific location-based limitations on where those drugs are administered.

In essence, it aims to remove cost and access barriers to drugs that are administered by clinicians (as opposed to self-administered at home), ensuring parity with other covered medications and workflows.

Key provisions and changes

Mandated coverage: Health insurance plans subject to the bill must cover clinician-administered drugs.

No additional financial penalties: The bill prohibits plan designs from imposing extra out-of-pocket costs, coinsurance, copays, or deductibles specifically for clinician-administered drugs beyond what would normally apply to covered drugs.

Location-agnostic administration: Plans may not restrict or condition coverage on the setting where the clinician-administered drug is provided. This implies coverage should be available regardless of whether the drug is given in a physician’s office, clinic, hospital outpatient department, or other approved clinical setting.

Scope of coverage: While the summary does not specify all classes of clinician-administered drugs, the implication is that drugs administered by a clinician (as defined by relevant medical guidelines) fall under the required coverage.

Compliance and enforcement: The bill would require applicable entities to comply and likely include standard enforcement mechanisms typical for health coverage parity provisions (though specific enforcement language is not provided in the summary).

Who is affected

Insurers and health benefits sponsors subject to New Jersey health coverage requirements.

Plan beneficiaries and enrollees who receive clinician-administered drugs, who would gain coverage parity and reduced financial barriers.

Healthcare providers who administer clinician-delivered therapies, potentially increasing patient access and reducing care delays due to coverage or cost concerns.

Procedural and timeline aspects

Introduction and referral: Introduced and referred on June 15, 2026, to the Assembly Financial Institutions and Insurance Committee.

Sponsor: Co-sponsored by Assemblymember Carol Murphy.

Next steps (typical for this stage): Committee review, potential amendments, and subsequent votes in the Assembly, and then likely consideration by the Senate if advanced.

Potential impact and considerations

Access and affordability: By removing penalties and location-based restrictions, patients may experience easier access to clinician-administered therapies and more predictable cost sharing.

Plan design implications: Insurers may need to adjust their formularies, benefit design, and provider-network contracts to ensure compliance and uniform coverage across settings.

Administrative simplicity: Standardizing coverage criteria could reduce administrative burdens for clinicians and patients when scheduling and administering these therapies.

If you’d like, I can tailor this summary to a specific audience (e.g., policymakers, insurers, patients) or compare it to existing New Jersey coverage parity statutes for clinician-administered drugs.